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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess beneficial and adverse effects of psychological treatment versus active alternative treatment or no treatment in adults with
migraine, using methods that allow comparison with reviews of psychological interventions for other painful conditions.
B A C K G R O U N D
Description of the condition
Migraine is a commonly experienced condition and prevalence
is estimated to be between 14% and 16% (Stovner 2007). The
Global Burden of Disease study indicated that migraine was the
third most prevalent of all medical conditions (Vos 2012), and
ranked the burden associated with migraine as the highest of any
neurological disorder (Leonardi 2013). The cost of migraine is
estimated to be EUR 1222 per person per year, which amounts
to an estimated EUR 50 to 111 billion annually across Europe
(Linde 2012). Similar estimates from theUSA suggest that chronic
migraine is associated with costs of USD 1036 per person per year
and in Canada of CAN 471 per person per year (Stokes 2011).
The International Headache Society (IHS) defines four types of
primary headache: migraine, tension-type headache, trigeminal
autonomic cephalgias and other primary headache disorders (IHS
2013). This Cochrane Review will focus on migraine in adults.
The twomajor subtypes ofmigraine aremigrainewith andwithout
aura. An aura refers to neurological symptoms that are noticed
shortly before the migraine begins. Migraine may also be classified
as either chronic or episodic: chronic migraine is distinguished
from episodic migraine by headache occurrence on 15 or more
days per month for at least three months, with migrainous features
on at least eight days per month (IHS 2013).
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Migraines without aura
Migraine without aura is an episodic, recurrent condition charac-
terized by a specific set of symptoms and features that distinguish
it from other forms of headache (e.g. cluster headache or tension-
type headache). IHS criteria are as follows.
• At least five attacks that fulfil the following conditions (B to
D).
• The attacks last four to 72 hours (untreated or
unsuccessfully treated).
• Headaches have two of the following four characteristics:
◦ unilateral location;
◦ pulsating quality;
◦ moderate or severe pain intensity;
◦ aggravation by or causing avoidance of routine
physical activity.
• During headache one of the two following:
◦ nausea or vomiting, or both;
◦ photophobia and phonophobia.
• Not better accounted for by another International
Classification of Headache Disorders - 3 (ICHD-3) diagnosis
(IHS 2013).
Migraines with aura
In addition to migraines without aura, some people experience
migraine with aura, which is characterized by neurological symp-
toms that typically precede and predict the headache, although for
some patients these symptoms can continue with the headache.
IHS criteria are as follows.
• At least two attacks that fulfil conditions B and C.
• One or more of the following fully reversible aura
symptoms:
◦ visual symptoms;
◦ sensory symptoms;
◦ speech and language;
◦ motor;
◦ brainstem;
◦ retinal.
• Headaches have at least two of the following four
characteristics:
◦ at least one aura symptom spreads gradually over ≥
five minutes, or two or more symptoms that occur in succession,
or both;
◦ each individual aura symptom lasts for between five
and 60 minutes;
◦ at least one aura symptom is unilateral;
◦ the aura is accompanied or followed within 60
minutes by headache.
• Not better accounted for by another ICHD-3 diagnosis,
and transient ischaemic attack has been excluded.
In this review, we are interested in people who experiencemigraine
with typical aura, rather thanmigraine with brainstem aura, hemi-
plegic migraine or retinal migraine.
Description of the intervention
Our review aims to add to the currently available Cochrane Re-
view that investigates the efficacy of psychological interventions
for chronic pain excluding headache (Eccleston 2009; Williams
2012), and the Cochrane Review currently underway into psycho-
logical interventions for tension-type headache (McGuire 2014).
Most psychological treatments focus on the provision of skills that
individuals canuse to better copewith their symptomsofmigraine.
Typically, these skills include a range of cognitive and behavioural
strategies aimed at reducing stress, changing interpretations about
themigraine experience or dealing with the symptoms of migraine
once they occur. Hence we will employ the same definition of eli-
gible interventions as in those reviews: any credible psychological
treatment. To be defined as credible, the intervention will need to
do the following.
• include psychotherapeutic content that is clearly definable.
• be conducted by a healthcare professional appropriately
qualified to administer the intervention.
Therefore, we will exclude purely physical treatments (e.g. yoga).
We will ask trial authors for details about the training of therapists
in the trial, and ensure that we reach a consensus regarding the
inclusion of trials. We will include all modalities of intervention
including face-to-face individual or group treatment; telephone-
administered intervention or online treatment.
How the intervention might work
In addition to what is described above in Description of the
intervention, in the migraine literature, earlier programmes also
provided education to avoid triggers of migraine with a view to
reducing the frequency, but this approach has been criticized be-
cause such avoidance can lead to further sensitization to those trig-
gers and significantly restrict everyday activities. More recent ap-
proaches have included an element of exposure to triggers with a
view that peoplewill habituate during the exposure and thereby be-
come less sensitive to theirmigraine triggers (Martin 2009;Martin
2010).
Why it is important to do this review
The NICE guidelines for headache highlight the fact that psy-
chological therapies have been found to be effective for chronic
pain problems in general, and therefore have the potential to be
an important adjunct to medical management of headache and
related conditions, such as migraine (NICE 2012). Psycholog-
ical treatments that have the potential to reduce both the per-
sonal and economic burden associated with migraine are needed.
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Although there have been previous meta-analytic reviews of be-
havioural treatments, most have included all types of study designs
(e.g. before and after studies, randomized controlled trials (RCTs))
which has led to a possible overestimation of the treatment effect
(Rains 2005). The only meta-analysis that included only RCTs
was prepared on behalf of the Agency for Health Care Policy in
1999 (Goslin 1999) , and therefore it is important to have an up-
to-date synthesis of evidence. This review aims to fill that gap in
the literature.
O B J E C T I V E S
To assess beneficial and adverse effects of psychological treatment
versus active alternative treatment or no treatment in adults with
migraine, using methods that allow comparison with reviews of
psychological interventions for other painful conditions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include the following studies in the review.
• Randomized controlled trials (RCTs) and cluster RCTs.
• Studies should have at least 15 participants in any
treatment or control arm included in our analysis at the post-
treatment assessment.
Types of participants
Inclusion criteria
Adults (18 years or older) that report episodic or chronic migraine
with orwithout aura; if a trial includes other headache participants,
we will use data for migraine patients only if the trial authors
report the data separately. If data are unavailable separately for the
group with migraine, we will exclude. For the purposes of this
meta-analysis, we will not require International Classification of
Headache Disorders (ICHD) verified diagnoses, although we will
extract this data in order to examine diagnostic confirmation as a
potential mediator of response.
Exclusion criteria
We will exclude trials where the following occurs.
• Migraine is secondary to an acute or progressive
neurological condition (e.g. giant cell arteritis, raised intracranial
pressure, multiple sclerosis, infection).
• The primary pain complaint of the participant is not
migraine.
• Participants have a headache other than migraine (e.g.
tension-type headache, cluster headache, medication overuse
headache).
Types of interventions
Wewill include RCTs designed to test the efficacy of psychological
treatment as an active treatment of primary interest if at least one
arm of the trial provides a psychological intervention and there is a
comparison arm. We will define credible psychological treatment
as a treatment with definable psychotherapeutic content that an
appropriately qualified healthcare professional delivered or super-
vised. The comparison arm can include another active treatment
(psychological or medical), an attention-placebo (e.g. supportive
counselling) or other placebo group, routine care or waiting list
control. We will include all RCTs regardless of treatment dose, mi-
graine intensity and frequency, mode of delivery (e.g. individual,
group) or medium of treatment delivery (e.g. face-to-face, Inter-
net).
Types of outcome measures
Wewill include outcomes as either categorical or continuous data.
The following outcomes draw on the recommendations proposed
by the International Headache Society Clinical Trials Subcommit-
tee (Tfelt-Hansen 2000) and the guidelines for behavioural treat-
ments of recurrent headache (Penzien 2005).
Primary outcomes
• Reduction in migraine frequency (we define migraine
frequency as the number of days with migraine in a four week
period based on participant report using a headache diary).
Secondary outcomes
• Responder rate: percentage of participants for whom there
was a reduction of 50% or greater in attack frequency in the four
weeks after treatment. As smaller symptom reductions can also
be meaningful for participants, and in order to be comparable to
the review McGuire 2014 proposed, we will also calculate
responder rate for those participants that experience a 30% or
greater reduction in symptoms.
We will investigate the secondary outcomes below to compare
measures before and after psychological therapy compared to con-
trol. Hence, the outcome refers to the reduction in each measure.
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• Migraine intensity (average intensity of migraine headache
based on a simple numerical rating scale measuring pain
intensity from mild, moderate to severe).
• Migraine duration (number of hours of migraine per day
from a headache diary).
• Number of days with migraine per four weeks.
• Mood (self-reported scales measuring depressive symptoms,
anxiety-related symptoms or distress, such as the Hospital
Anxiety and Depression Scales, Centre for Epidemiological
Study Depression Scale).
• Migraine medication usage (defined as (i) the number of
migraines that are treated with acute symptomatic treatment;
and (ii) the number of doses consumed).
• Self-reported questionnaire measures that assess the impact
of migraine on quality of life.
• Migraine-related disability.
• Adverse events (the proportion of participants that report
an adverse event during the study).
Search methods for identification of studies
Electronic searches
We will search the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library.
• MEDLINE (OVID).
• EMBASE (OVID).
• PsycINFO (OVID).
• CINAHL (EBSCO).
We will use Medical Subject Headings where applicable, and
also text word searching. The MEDLINE search strategy is in
Appendix 1. We will search for published and unpublished trials
in all languages.
Searching other resources
In order to ensure that all available trials are represented, we
will handsearch the reference lists of reviews and included tri-
als, and perform citation searches of included trials and identi-
fied reviews. We will search the metaRegister of controlled tri-
als (mRCT) (www.controlled-trials.com/mrct), clinicaltrials.gov
(www.clinicaltrials.gov) and the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
(http://apps.who.int/trialsearch/) for ongoing trials. In addition,
we will check reference lists of reviews and retrieved articles for
additional studies and will perform citation searches on key ar-
ticles. We will contact experts in the field for unpublished and
ongoing trials. We will contact study authors where necessary for
additional information.
Data collection and analysis
Selection of studies
Initially, we will merge the results of the individual searches and
remove all duplicates from the database search. Two review au-
thors will independently shortlist titles and abstracts of all identi-
fied articles. They will remove clearly irrelevant articles based on
titles and abstracts, and will consult a third review author in the
event of disagreement. Two review authors will independently as-
sess the full-text reports of relevant articles to determine whether
or not the design of the study meets the eligibility criteria. If there
is ambiguity about whether a trial meets the inclusion criteria,
we will contact the study authors for clarification. Finally, we will
link multiple reports on the same study for the purposes of data
extraction. Two review authors will list the full-text articles that
are excluded in a Characteristics of excluded studies table, with
the reason(s) for exclusion. To promote transparency of the search
and systematic review process, we will produce a PRISMA flow
diagram, as recommended in Chapter 6 of the Cochrane Hand-
book (Higgins 2011).
Data extraction and management
We will develop a data extraction form modified from those de-
veloped for similar Cochrane Reviews (e.g. McGuire 2014). We
will extract data on important characteristics of the study design,
characteristics of participants, diagnosis (migraine with or with-
out aura), duration of migraine, type of intervention, treatment
dosage,migraine intensity and frequency,mode of treatment deliv-
ery (e.g. individual treatment, face-to-face, group, Internet), con-
trol intervention, qualifications of the therapist and outcomemea-
sures. Two review authors will independently extract data from
each of the included studies, and will enter these data into Charac-
teristics of included studies tables in Review Manager (RevMan)
(RevMan 2014). They will consult a third review author, if nec-
essary, to resolve any disagreements.
Assessment of risk of bias in included studies
We will assess the risk of bias for each included study using the
criteria developed in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). Two review authors will assess
the following risks for biases and will resolve any discrepancies
through consensus. The review authors will enter data into the
Risk of bias tables and provide support for each judgement. We
will also construct a Risk of bias figure(s).
Random sequence generation
Wewill determine themethod the trial authors utilized to generate
a random sequence.Wewill judge the trial to be at a low risk of bias
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if the trial authors used a random method to assign participants
to conditions (e.g. computerized generation of number sequence;
toss of a coin, random number table etc). If the trial authors do not
state themanner in which they determined randomization and are
unable to provide this data, we will consider the study to have an
unclear risk of bias. Where the trial does not determine random-
ization using a truly random procedure (e.g. counterbalanced, use
of odd and even numbers etc), we will describe the study as having
a high risk of bias.
Allocation concealment
We will assess the method the trial authors used to conceal allo-
cation prior to assignment. We will rate those studies that ade-
quately concealed allocation as having a low risk of bias. Where
the concealment is unclear, we will deem the study to have an un-
clear risk of bias. Where the allocation sequence was available to
investigators prior to randomization, we will determine the study
to have a high risk of bias for this item.
Blinding of outcome assessment
Since psychological treatments cannot blind personnel involved in
treatment delivery and can rarely blind participants, we will assess
the risk of bias using the following.
• Equivalence of treatment expectations of participants across
study arms
• Presentation of third party outcome assessments where the
third party is blind to treatment allocation.
We will deem studies that blinded the assessors to the condition to
which the participant was allocated or where treatment expectancy
is shown to be equivalent as at low risk of bias. Where the trial
authors do not state whether or not blinding was involved, we will
rate the study as having an unclear risk of bias. Where outcome
assessors were not blinded and the trial authors perform any as-
sessment of treatment expectation, we will assign a high risk of
bias.
Accounting for attrition
When participants are lost to follow-up, this introduces a source
of potential bias to trials. Hence, we will include a measure of the
completeness of the follow-up data and how study authors dealt
with cases of missing data. We will judge studies to have a low
risk of bias where there is a high proportion of participants who
start the treatment that complete follow-up assessments (≥ 90%
data available) or where most (more than 70%) data are available
and we will perform an intention-to-treat analysis (ITT) using a
multiple imputation model. Where these criteria have not been
met and high rates of attrition are present or ITT analyses rely on
less stringent methods (e.g. last-observation-carried-forward), we
will judge the trial as at a high risk of bias.
Selective reporting
We will identify entries in clinical registries for all clinical trials
we include in the analyses to determine whether the trial authors
analysed all primary and secondary end-points in the way in which
they had originally planned. We will deem those studies that re-
port all end-points using the analyses set out in the trial register
to be of low risk of bias. Where a pre-registered trial is unavail-
able, the level of bias will remain unclear. Where pre-registered
information demonstrates that the trial authors reported different
primary outcomes or did not report all measures in the final trial
report or performed a selective analysis, we will assign a judgement
of high risk of bias for that study. If a protocol is unavailable, we
will deem the study as at high risk of bias.
Treatment integrity
We will include two items to determine the integrity of the in-
tervention administered. The first relates to the training of the
therapist. We will deem trials that report on specific training of
an appropriately qualified therapist for the purposes of the trial to
be of low risk. The second item relates to treatment fidelity. We
will judge trials that have a dedicated treatment manual and report
an assessment of the degree to which therapists adhered to that
manual to be of low risk. In order to be deemed at low risk of bias,
protocols need to have both sufficient training and fidelity checks.
We will only consider trials to be at low risk of bias if the therapists
are well trained and there is evidence of treatment fidelity.
Other sources of bias
We will determine whether or not each included study was appar-
ently free or not of other problems that could put it at a high risk
of bias. For example, sources of funding that could be perceived
as a conflict of interest, or small size of the trial could confirm
an additional risk of bias. The Cochrane Pain, Palliative and Sup-
portive Care (PaPaS) Review Group recommends the following
for assessing the risk associated with the size of a study and hence
we will use the conventions outlined below.
• Low risk of bias: more than 200 participants per treatment
arm.
• High risk of bias: fewer than 50 participants per treatment
arm.
• Unclear risk of bias: between 50 and 199 participants per
treatment arm.
Measures of treatment effect
Where data are continuous, wewillmeasure the standardizedmean
difference between the psychological treatment arm and the com-
parator arm (with 95% confidence intervals (CIs)). Where data
are categorical (e.g. proportion of responders), we will determine
the risk ratio (RR) and number needed to treat (NNT) for≥ 50%
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or ≥ 30% reduction in attack frequency over four weeks, for the
intervention versus control group.
We will assess the standardized mean difference post-treatment
and at follow-up. In the case ofmultiple time-points, wewill define
post-treatment as the assessment that is closest to the end of the
intervention and within three months. In the case of follow-up,
assessment must be made between three and 12 months after the
end of the intervention. If more than one follow-up period meets
this criterion, thenwe will use the longest available follow-up data.
Unit of analysis issues
We will analyse the trials arms separately but halve the N of the
comparator arm where more than two active treatment arms meet
criteria for a credible psychological treatment and are compared
to one comparator arm. This is in order not to overly weight the
results of that study where both arms are included in the same
analysis.
Dealing with missing data
If data are missing from the original publication, we will contact
the trial authors directly and request that they provide sufficient
data to be able to calculate the effect size of interest.Wewill contact
the trial authors and will give them one month to respond, and we
will send a reminder email at the end of a month to give them a
further week to provide the data. This includes studies where only
a headache index is reported. In these instances we will contact the
trial authors by email to provide the data on which they calculated
the headache index was calculated. Where standard deviations are
missing and unobtainable from the trial authors, we will calculate
these where possible from F, t, or Pp values, or from standard error
values. If this is not possible, we will treat the trial as though it
has no useable data. We will consider the potential impact on the
results of the missing data in the ’Discussion’ section of the review.
Assessment of heterogeneity
We will assess heterogeneity by examining the CIs for each study
and using the I² statistic and the Chi² statistic for each of the
primary and secondary outcomes. If there is considerable hetero-
geneity, we would need to justify the combination of data from
the studies. We will consider the implications of this decision in
the ’Discussion’ section of the review.
Assessment of reporting biases
We will assess the likelihood that publication bias affected the re-
sults of the meta-analysis by inspection of known protocols that
were registered and not published.Wewill also use statistical meth-
ods to test for likely publication bias including the examination
of funnel plots and the use of the trim and fill method.
Data synthesis
We will use Review Manager (RevMan) to analyse the data
(RevMan 2014), and will use a random-effects model. We will
include a ’Summary of findings’ table of the main outcomes in the
results section, which we will construct using GRADEpro Guide-
line Development Tool (GDT) (GRADEpro GDT 2015). We
will rate the overall confidence in our findings using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) system (Appendix 2). We will determine whether fu-
ture research is likely to influence the findings, and therefore what
level of confidence we can have in the results.
Subgroup analysis and investigation of heterogeneity
We intend to examine the relative effectiveness of treatments for
different levels of frequency of migraine at pre-treatment (three
or more attacks per four weeks versus less than three attacks ev-
ery four weeks). We have chosen this frequency to be consistent
with the reporting of outcomes for the tension headache protocol
(McGuire 2014). In addition, we will investigate the relative ef-
ficacy of interventions for those with chronic versus episodic mi-
graine; and participants with migraine with and without aura, if
sufficient data are available. If sufficient data are available, we will
also include whether participants in the study had ICHD-verified
diagnoses of migraine.
In terms of treatment characteristics, we also intend to analyse sep-
arately those interventions with face-to-face treatment compared
to those with only or predominantly phone or Internet contact,
and group versus individual mode of delivery. We also plan to ex-
amine separately the effectiveness of cognitive behaviour therapy
in the treatment of migraine. Should sufficient trials meet the in-
clusion criteria of this review, we will examine the relative efficacy
of relaxation compared to biofeedback. Finally, if we include a suf-
ficient number of trials, we will analyse those whose approach is to
encourage avoidance of migraine triggers with those that advocate
exposure to triggers.
Sensitivity analysis
Wehave planned no sensitivity analyses a priori, because we believe
that the evidence base is likely to be too small for sensitivity analyses
to be meaningful or reliable.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy (via OVID)
1 exp Psychotherapy/
2 psychotherap*.tw.
3 (psycho* adj3 therap*).tw.
4 Counseling/
5 counsel*.tw.
6 exp Behavior Therapy/
7 (relaxation or imagery or (behavio#r adj3 therap*)).tw.
8 biofeedback.tw.
9 (stress adj2 manag*).tw
10 or/1-9
11 exp Migraine Disorders/
12 (migrain* or (sick adj1 headache*)).tw.
13 11 or 12
14 10 and 13
15 randomized controlled trial.pt.
16 controlled clinical trial.pt.
17 randomized.ab.
18 placebo.ab.
19 drug therapy.fs.
20 randomly.ab.
21 trial.ab.
22 groups.ab.
23 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24 exp animals/ not humans.sh.
25 23 not 24
26 14 and 25
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Appendix 2. GRADE: assessing the quality of the evidence
We have taken this section from the Cochrane Drugs and Alcohol Group recommended text. We will assess the overall quality of the
evidence for each outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach
(GRADEpro GDT 2015) and present the main findings of the review in a transparent and simple tabular format in the ’Summary
of findings’ tables. In particular, we will include key information concerning the quality of evidence, the magnitude of effect of the
interventions examined, and the sum of available data on the main outcomes.
The GRADE system assesses the quality of the evidence as at one of the following four levels of quality.
• High: further research is very unlikely to change our confidence in the estimate of effect.
• Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the
estimate.
• Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
• Very low: any estimate of effect is very uncertain.
We will downgrade the quality of the evidence by the value we have given in brackets if there is:
• Serious (−1) or very serious (−2) limitation to study quality.
• An important inconsistency (−1).
• Some (−1) or major (−2) uncertainty about directness.
• Imprecise or sparse data (−1).
• A high probability of reporting bias (−1).
C O N T R I B U T I O N S O F A U T H O R S
LS, IM and BM developed the concept for this review. LS wrote the first draft of the protocol, and all protocol authors commented
on it. LS revised the protocol after all protocol authors commented. All protocol authors read and approved the final version of the
protocol.
D E C L A R A T I O N S O F I N T E R E S T
LS: none known. LS is a clinical psychologist and practices CBT with patients with a range of chronic health problems.
AW: none known.
PRM: none known. PRM is a clinical psychologist and practices CBT for patients with headache and migraine.
MN: none known.
MW: none known. MW is a clinical psychologist and practices CBT for patients with chronic pain.
IM: none known.
AB: none known; AB is a clinical psychologist and practices CBT for patients with a range of mental health problems.
JD: none known.
BM: none known. BM is a clinical psychologist and practices CBT for patients with headache and chronic pain.
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